Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific) ‐ not measured · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dalteparin vs placebo

Hospitalisation (number and duration) ‐ not measured · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dalteparin vs placebo

Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) ‐ not measured · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dalteparin vs placebo

Adverse events associated with the use of anticoagulants (e.g. bleeding) ‐ not measured · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tinzaparin vs placebo

Pain durationScale from: 1 to 7. · people with sickle cell disease

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 253 participants
Very low

Tinzaparin vs placebo

The requirement for opiate treatment · people with sickle cell disease

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 253 participants
Very low

Tinzaparin vs placebo

Number of serious complications of SCD ‐ not measured · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tinzaparin vs placebo

Number of other sickle‐related events ‐ not measured · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tinzaparin vs placebo

Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire either generic or SCD specific) ‐ not measured · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tinzaparin vs placebo

Hospitalisation (number and duration) ‐ not measured · people with sickle cell disease

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 253 participants
Very low

Tinzaparin vs placebo

Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific) ‐ not measured · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tinzaparin vs placebo

Adverse events associated with the use of anticoagulants (e.g. bleeding) · people with sickle cell disease

Tinzaparin showed no clear difference in adverse events associated with the use of anticoagulants (e.g.… compared with placebo (low certainty).

1 finding from 1 review

Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only
RR 4.96 [0.24, 102.31]
1 study · 253 participants
Low